Comparison
Abeta Amyloidosis Iowa Type C3888309 vs 17q24 2 Microdeletion Syndrome C5680185
Clinical comparison between Abeta Amyloidosis Iowa Type and 17q24 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
Abeta Amyloidosis Iowa Type C3888309
Genetic form of cerebral amyloid angiopathy caused by APP gene mutation. Inherited condition. Associated with cognitive decline and brain bleeding.
17q24 2 Microdeletion Syndrome C5680185
A rare genetic disorder caused by deletion of genetic material on chromosome 17. Individuals may have developmental delays, facial features, and other medical issues. Care is supportive and multidisciplinary.
6 comparison axes
Onset
Abeta Amyloidosis Iowa Type C3888309
50-65
17q24 2 Microdeletion Syndrome C5680185
0-null
Onset patterns differ
Severity
Abeta Amyloidosis Iowa Type C3888309
severe
17q24 2 Microdeletion Syndrome C5680185
moderate
Different severity levels
Chronic
Abeta Amyloidosis Iowa Type C3888309
Chronic
17q24 2 Microdeletion Syndrome C5680185
Chronic
Differing course
Communicable
Abeta Amyloidosis Iowa Type C3888309
No
17q24 2 Microdeletion Syndrome C5680185
No
Different transmission
Body System
Abeta Amyloidosis Iowa Type C3888309
neurologic
17q24 2 Microdeletion Syndrome C5680185
congenital
Same/different system
Category
Abeta Amyloidosis Iowa Type C3888309
rare-disease
17q24 2 Microdeletion Syndrome C5680185
genetic
Different category
Bottom line
abeta-amyloidosis-iowa-type-C3888309 and 17q24-2-microdeletion-syndrome-C5680185 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abeta Amyloidosis Iowa Type C3888309 | 17q24 2 Microdeletion Syndrome C5680185 | Discriminating power |
|---|---|---|---|
| Age at first concern | Typically recognized in adulthood, reported around ages 50–65. | Present from birth or early development; exact onset range is not fully specified. | High |
| Neurologic course | Progressive cognitive decline with risk of brain bleeding. | Developmental delay may occur; progressive vascular brain disease is not established. | High |
| Congenital features | Not described as a congenital malformation syndrome. | May include characteristic facial features and other medical issues. | Moderate |
When to favor each condition
Choose Abeta Amyloidosis Iowa Type C3888309 when
Adult-onset cognitive decline with suspected brain hemorrhage
Fits the described neurologic pattern of Iowa-type Aβ amyloidosis better than a congenital deletion.
Moderate
Family history suggesting inherited APP-related disease
The condition is described as an inherited APP mutation, pending confirmatory genetics.
Moderate
No congenital developmental syndrome
Absence of early developmental features makes the microdeletion less likely, but does not prove the diagnosis.
Low
Choose 17q24 2 Microdeletion Syndrome C5680185 when
Congenital or early developmental concerns
Early onset and developmental delay align with the microdeletion description.
Moderate
Facial or multisystem congenital findings
These features are described for the deletion and not for Iowa-type amyloidosis.
Moderate
Chromosomal deletion identified at 17q24.2
A confirmed deletion supports this diagnosis over an APP-related amyloidosis.
High
How key tests differ
| Test | Abeta Amyloidosis Iowa Type C3888309 | 17q24 2 Microdeletion Syndrome C5680185 | Interpretation |
|---|---|---|---|
| Genetic testing | APP variant consistent with Iowa-type amyloidosis may be sought. | Chromosomal testing may show a 17q24.2 microdeletion. | A confirmed result distinguishes the conditions; clinical suspicion alone is insufficient. |
| Brain imaging | May be used to evaluate reported brain bleeding; specific findings are not fixed here. | No characteristic brain-bleeding pattern is established from the supplied data. | Imaging supports assessment but should be interpreted by a clinician. |
| Developmental evaluation | Not the primary described presentation. | May document developmental delay and functional needs. | Useful for the deletion phenotype, not diagnostic by itself. |
Prognosis comparison
Abeta Amyloidosis Iowa Type C3888309
- Outcome
- Described as severe and chronic, with cognitive decline and bleeding risk; exact survival is not established.
- Factors
- APP-related disease, adult onset, neurologic complications.
17q24 2 Microdeletion Syndrome C5680185
- Outcome
- Described as moderate and chronic, with variable developmental and medical needs.
- Factors
- Deletion extent, developmental profile, and associated medical issues.
Time frame: Lifelong course; left usually recognized in later adulthood, right from early life.
Individual genetics, complications, supports, and clinician-guided care strongly influence outcomes.
Complications comparison
| Complication | Presentation |
|---|---|
| Brain bleeding | Described association; frequency and severity vary and are not quantified here. Not established from the supplied description. Any suspected bleeding needs urgent clinical assessment. |
| Cognitive or developmental impairment | Adult cognitive decline is described. Developmental delay may occur. The timing and mechanism differ; trajectories are individualized. |
| Other medical issues | Beyond neurologic disease, additional complications are not established here. Other medical issues may occur and require multidisciplinary care. Do not assume a specific complication without evaluation. |
Patient education highlights
- HighDifferent conditions
These are separate genetic disorders with different ages of onset and clinical patterns.
- HighConfirmation
A clinician and genetics specialist should confirm the diagnosis; labels alone are not enough.
- MediumCare planning
Iowa-type disease centers on neurologic monitoring; the deletion generally needs supportive, multidisciplinary care.